Furthermore, a new orally bioavailable GLP-1RA, oral hypoglycemic peptide 2 (OHP2), can confer protective effects on diabetic cardiomyopathy through rescuing cardiac lipotoxicity by inhibiting Rho (the small GTPase) kinase (ROCK)/PPAR pathway [89, 90] (Figure 1)
Those differences in manufacturing, ingredients and formulations are exactly what has some clinicians worried about their patients use of compounded GLP-1s
Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
(2024, 1 octobre)
How to save money on retatrutide Retatrutide costs what it costs, but how you access it determines what you actually pay
[2] [3] It belongs to a novel class of agents known as triple hormone receptor agonists , meaning it simultaneously activates three distinct receptors involved in appetite regulation and energy metabolism: GLP-1 (glucagon-like peptide-1) receptor reduces appetite and slows gastric emptying GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin secretion and, based on preclinical and early clinical evidence, may contribute to improved fat metabolism Glucagon receptor preclinical and early clinical data suggest activation of this receptor may increase energy expenditure and promote fat breakdown (lipolysis), though the precise contribution in humans is still being characterised This triple-action mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist)
